Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study documented a 36-year-old woman with postpartum-onset frontal fibrosing alopecia who showed significant improvement in hair regrowth after early combination therapy with dutasteride, tofacitinib, and intralesional triamcinolone acetonide, suggesting potential benefits of multimodal treatment in this typically irreversible condition.

Lichen planopilaris and frontal fibrosing alopecia are likely distinct diseases with different tissue involvement.

In this study, patients with lichen planopilaris and frontal fibrosing alopecia reported a substantial impairment in quality of life and experienced high levels of stress, often considering stress a cause of their condition.

This consensus from 22 Spanish dermatologists recommends using a multimodal therapy starting with oral dutasteride, combined with topical and/or intralesional agents, and adding hydroxychloroquine if inflammation persists, to manage frontal fibrosing alopecia due to its irreversible hair loss and lack of specific approved treatments.

This review found that hair transplantation in patients with primary cicatricial alopecias is a viable option when the disease is stable, with outcomes varying significantly by subtype.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

This study found that patients with primary cicatricial alopecia are at higher risk of developing various comorbidities, including systemic lupus erythematosus, hypothyroidism, and dermatological conditions, compared to controls.

This review discusses the possible link between cosmeceuticals and frontal fibrosing alopecia but reports no conclusive findings; the authors stress further research on environmental triggers is needed.

This study surveyed 85 alopecia patients from a specialist clinic, revealing frequent barriers to timely and accurate diagnosis and treatment, with many reporting significant delays and dissatisfaction with initial care from general practitioners before accessing specialist dermatology services.

This reported case of lichen planopilaris in siblings suggests a potential genetic predisposition, supporting the hypothesis of inherited susceptibility in this condition.

This study reports that high-frequency ultrasound can characterize frontal fibrosing alopecia by assessing dermal atrophy, hair follicle changes, and subclinical inflammation.

In this case study, a 74-year-old patient with frontal fibrosing alopecia displayed unique trichoscopic and histopathological features, and treatments like 5-alpha reductase inhibitors and oral minoxidil effectively halted disease progression, highlighting the importance of comprehensive facial analysis for prognosis.

This review discusses the unique clinical features, challenges in diagnosis, and treatment protocols of frontal fibrosing alopecia in men, noting the overlap with other types of alopecia and the need for further studies.

According to this review, frontal fibrosing alopecia in men exhibits unique clinical features and is often misdiagnosed, underscoring the need for validated diagnostic criteria and treatment evaluation.

In this narrative review, researchers evaluated existing literature on the treatment of frontal fibrosing alopecia, finding that while no curative treatment exists, clinical improvements can be achieved through personalized and combined therapy approaches.

This abstract discusses the prevalence and forms of lichen planopilaris, a type of scarring hair loss, but reports no new clinical findings.

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

In this study of a Colombian sample, the researchers found that while sex, alopecia location, and symptoms aligned with global reports, age at presentation, tobacco use, and use of wigs and dyes were different from those noted in other countries.

In this retrospective study, oral minoxidil was found to improve the density of the frontotemporal hairline in 45.1% of patients with frontal fibrosing alopecia, with some also experiencing eyebrow and eyelash growth; however, adverse effects such as hypertrichosis were noted in 33.6% of the participants.

This study reports the prescribing preferences of UK dermatologists for treating various hair loss conditions, noting that topical corticosteroids for mild to moderate alopecia areata and topical minoxidil for female pattern hair loss are commonly used first-line treatments.

This study found that phenoxyethanol is the most common contact allergen in over-the-counter hair loss products, but its role in the development or exacerbation of frontal fibrosing alopecia remains unclear.

This study evaluates the effectiveness of hydroxychloroquine in treating lichen planopilaris, suggesting varying success based on a real-life retrospective analysis.

In this clinical trial, 16 women with frontal fibrosing alopecia experienced significant improvements in hair density, vellus hair count, and quality of life after monthly intralesional dutasteride treatments, though larger and longer-term studies are needed to confirm these findings.

In this study, researchers identified genetic factors associated with frontal fibrosing alopecia, noting a protective effect of a specific CYP1B1 gene variant, which may offer insights into the disease's pathogenesis and future risk mitigation strategies.

In this case study, a 36-year-old male with symptoms of keratosis pilaris atrophicans faciei and frontal fibrosing alopecia tested negative for a specific mutation, highlighting genetic testing's potential to improve diagnosis and treatment outcomes in these similar conditions.

This review discusses various therapeutic options for frontal fibrosing alopecia and highlights the need for more research, as existing data are largely retrospective and lack precise treatment guidelines.

In this pilot study, participants with lymphocytic primary cicatricial alopecia who applied 6% topical gabapentin solution twice daily for 12 weeks experienced significant symptom reduction, though there was no noticeable change in nerve fibre density or neuropeptide expression.

This study found that oral isotretinoin significantly reduced symptoms in nearly 90% of patients with frontal fibrosing alopecia, affecting both facial papules and hair loss.

This review discusses the potential link between contact allergy and frontal fibrosing alopecia, noting the presence of implicated allergens in current literature, but reports no new clinical findings.

The researchers in this study identified molecular mechanisms involved in frontal fibrosis alopecia, highlighting immune response and fatty acid metabolism, and developed a four-gene diagnostic model showing high accuracy in distinguishing affected individuals from controls.